Exclusive: Exscientia to use AI in proposed fast-track development of ‘low-cost’ pill for Sars viruses
Exscientia, an Oxford-based firm that uses artificial intelligence to develop medicines, has won a $1.5m grant from the Bill & Melinda Gates Foundation to create a Covid-19 treatment that also works for new mutations or other Sars viruses.
The company, a spin-off from the University of Dundee, is based at the Oxford Science Park. It counts Japan’s SoftBank, the fund manager BlackRock, and the US drug firm Bristol Myers Squibb among its financial backers.
